Covid-19 roundup: BioNTech exec says new production sites could be added to meet demand — report; Giving up on the EC, Valneva looks to individual countries for vaccine supply deals
BioNTech CFO Sierk Poetting says he isn’t ruling out the construction of new production sites to meet demand for its Pfizer-partnered Covid-19 vaccine.
Poetting told the Handelsblatt newspaper, published in Düsseldorf, Germany, that the company is in talks to ramp up capacity, which could be done in six months if necessary.
“There is still room for improvement. But that will ultimately also depend on demand,” he said, per Reuters.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
